Rosetta Genomics (ROSG) - microRNA Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rosetta Genomics (ROSG) - microRNA

ROSG 0.430

0.0%

May 21 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Lokness who wrote (28)	1/17/2009 7:17:16 PM
From: tuck	Read Replies (1) of 58

Wow, I started something there! I guess I was being a little harsh. The PR had all the platitudes you see spouted when early stage research in dx shows a hint of progress. They'd still have to do trials in humans, and they don't really own up to the probable length of time to commercialization. That said, it could indeed make some sense as an initial screening tool, given its non-invasive nature and reasonable sensitivity. There are other tests which fail on the sensitivity side, but are more specific, maybe these could be combined. Anyhow, here's a somewhat dated look at screening options and their sensitivities and specificities. Predictive values (which depend on expected incidence) aren't given: ahrq.gov Sorry to hear about losing a relative to a perforation. That is an issue. Happens a little less than 1% of the time, but since many of these are done, that's a lot in absolute numbers . . . Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next